Código QR (código de barras bidimensional)

Pembrolizumab in combination with tocilizumab in high-risk hospitalized patients with COVID-19 (COPERNICO): A randomized proof-of-concept phase II study

Objectives: Severe COVID-19 is associated with immune dysregulation and hyperinflammation (lymphocyte exhaustion and elevated interleukin 6. Pembrolizumab (P; immune-activating anti-programmed cell death-1 antibody) plus tocilizumab (TCZ; anti- interleukin 6 receptor antibody) might interrupt the hy...

ver descrição completa

Na minha lista:
Principais autores: Matilde Sánchez-Conde, Pilar Vizcarra, José Manuel Pérez-García, María Gion, María Pilar Martialay, Javier Taboada, Alberto Alonso-Fernández, Miguel Sampayo-Cordero, Andrea Malfettone, Isabel Tena, Sergio De La Torre, Antonio Llombart-Cussac, Javier Cortés
Formato: Artigo
Idioma:Inglês
Publicado em: Elsevier 2022-10-01
coleção:International Journal of Infectious Diseases
Assuntos:
Pembrolizumab
Tocilizumab
COVID-19
SARS-CoV-2 infection
Acesso em linha:http://www.sciencedirect.com/science/article/pii/S1201971222004751
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registros relacionados